title: Use of an inverse agonist radioligand [3H]A-317920 reveals distinct pharmacological profiles of the rat histamine H3 receptor.
abstract: Selective radioligands for histamine H(3) receptors have been used to characterize H(3) receptor pharmacology by radioligand binding assays and to determine H(3) receptor distribution by tissue autoradiography. Here we report the synthesis and receptor binding characterization of [(3)H]A-317920 (furan-2-carboxylic acid(2-[4-[3-([3,5-(3)H]4-cyclopropanecarbonyl-phenoxy)-propyl]-piperazin-1-yl]-1-methyl-2-oxo-ethyl)-amide), a high affinity inverse agonist radioligand for the rat H(3) receptor. The binding of [(3)H]A-317920 to rat cortical and cloned H(3) receptors revealed fast on- and slower off-rate kinetics with calculated K(d) values in agreement with those determined in saturation binding assays (0.2 nM for both receptors). Further, we compared [(3)H]A-317920 with the agonist [(3)H](N)-alpha-methylhistamine ([(3)H]NalphaMH) as radioligand tools to study receptor pharmacology. Agonists and antagonists displaced [(3)H]NalphaMH with one-site binding characteristics and Hill slopes approached unity. In contrast, although antagonists exhibited one-site binding, [(3)H]A-317920 displacement by agonists was best fit by two-site binding models, and the potencies of the high affinity, GDP-sensitive sites correlated with the potencies defined in [(3)H]NalphaMH binding. Unlike [(125)I]iodoproxyfan, [(3)H]A-317920 exhibits potent and selective binding to rat H(3) receptors with low binding to non-H(3) sites, including cytochrome P450. These findings show that [(3)H]A-317920 is a potent rat H(3) receptor antagonist radioligand and has utility for studying H(3) receptor pharmacology.
authors.affiliation: Neuroscience Disease Research, Global Pharmaceutical Research & Development, Abbott Laboratories, Abbott Park, IL 60064, USA. betty.yao@abbott.com
authors.forename: B Bei
authors.initials: BB
authors.lastname: Yao
authors.forename: D G
authors.initials: DG
authors.lastname: Witte
authors.forename: T R
authors.initials: TR
authors.lastname: Miller
authors.forename: T L
authors.initials: TL
authors.lastname: Carr
authors.forename: C H
authors.initials: CH
authors.lastname: Kang
authors.forename: S
authors.initials: S
authors.lastname: Cassar
authors.forename: R
authors.initials: R
authors.lastname: Faghih
authors.forename: Y L
authors.initials: YL
authors.lastname: Bennani
authors.forename: B W
authors.initials: BW
authors.lastname: Surber
authors.forename: A A
authors.initials: AA
authors.lastname: Hancock
authors.forename: T A
authors.initials: TA
authors.lastname: Esbenshade
mesh_terms: D000818:Animals; D002462:Cell Membrane / Q000502:physiology; D002540:Cerebral Cortex / Q000502:physiology; D003001:Cloning, Molecular; D006801:Humans; D007700:Kinetics; D010879:Piperazines / Q000378:metabolism* / Q000494:pharmacology; D011869:Radioligand Assay; D051381:Rats; D018100:Receptors, Histamine H3 / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D014316:Tritium
chemical_list: C475226:N-(2-(4-(3-(4-(cyclopropylcarbonyl)phenoxy)propyl)-1-piperazinyl)-1-methyl-2-oxoethyl)-2-furamide; D010879:Piperazines; D018100:Receptors, Histamine H3; D011994:Recombinant Proteins; D014316:Tritium